Holen Sie sich die Stockscreener-App
13.98
3.00%
-0.36
Schlusskurs vom Vortag:
$14.34
Offen:
$14.14
24-Stunden-Volumen:
108.19K
Relative Volume:
0.39
Marktkapitalisierung:
$367.94M
Einnahmen:
$31.38M
Nettoeinkommen (Verlust:
$-6.69M
KGV:
-53.77
EPS:
-0.26
Netto-Cashflow:
$-1.84M
1W Leistung:
+1.39%
1M Leistung:
-2.18%
6M Leistung:
+64.81%
1J Leistung:
+336.05%
1-Tages-Spanne:
$13.87
$14.58
1-Wochen-Bereich:
$13.53
$14.58
52-Wochen-Spanne:
$3.11
$18.41
Eton Pharmaceuticals Inc Stock (ETON) Company Profile
Firmenname
Eton Pharmaceuticals Inc
Sektor
Telefon
(847) 787-7361
Adresse
21925 W. FIELD PARKWAY, DEER PARK, IL
Vergleichen Sie ETON mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
ETON
Eton Pharmaceuticals Inc
|
13.96 | 367.94M | 31.38M | -6.69M | -1.84M | -0.26 |
|
ZTS
Zoetis Inc
|
145.49 | 67.28B | 9.26B | 2.49B | 2.30B | 5.47 |
|
HLN
Haleon Plc Adr
|
10.12 | 45.61B | 14.35B | 1.85B | 0 | 0.4023 |
|
TAK
Takeda Pharmaceutical Co Adr
|
14.82 | 45.01B | 30.25B | 1.37B | 5.08B | 0.4257 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
13.28 | 15.64B | 16.54B | -1.64B | 749.00M | -1.45 |
|
UTHR
United Therapeutics Corp
|
283.04 | 12.77B | 2.76B | 1.11B | 898.10M | 22.77 |
Eton Pharmaceuticals Inc Stock (ETON) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-01-23 | Bestätigt | H.C. Wainwright | Buy |
| 2025-01-10 | Eingeleitet | B. Riley Securities | Buy |
| 2025-01-06 | Bestätigt | H.C. Wainwright | Buy |
| 2024-09-04 | Fortgesetzt | H.C. Wainwright | Buy |
| 2024-05-06 | Eingeleitet | Craig Hallum | Buy |
| 2021-10-14 | Fortgesetzt | B. Riley Securities | Buy |
| 2021-01-04 | Bestätigt | H.C. Wainwright | Buy |
| 2019-09-20 | Eingeleitet | B. Riley FBR | Buy |
| 2019-06-10 | Eingeleitet | H.C. Wainwright | Buy |
Alle ansehen
Eton Pharmaceuticals Inc Aktie (ETON) Neueste Nachrichten
Eton Pharmaceuticals, Inc. (NASDAQ:ETON) Sees Large Increase in Short Interest - Defense World
Eton Pharmaceuticals, Inc. (NASDAQ:ETON) Has Found A Path To Profitability - Yahoo Finance
Raymond James Financial Inc. Makes New Investment in Eton Pharmaceuticals, Inc. (NASDAQ:ETON) - Defense World
Retail investors who have a significant stake must be disappointed along with institutions after Eton Pharmaceuticals, Inc.'s (NASDAQ:ETON) market cap dropped by US$35m - simplywall.st
(ETON) Technical Data - news.stocktradersdaily.com
Eton sells ex-U.S. rights for hormone disorder therapy to Esteve Pharma - MSN
Eton sells overseas rights for hormone disorder drug (ETON) - Seeking Alpha
Eton Pharmaceuticals Agrees to License International Rights for Increlex to Esteve Pharmaceuticals - MarketScreener
Eton Pharma Out-Licenses International Rights To Increlex To Esteve Pharma - Nasdaq
Eton Pharmaceuticals out-licenses international rights to Increlex - TipRanks
Eton Pharmaceuticals IncEsteve To Pay Eur4 Million Up Front For Increlex RightsSEC Filing - MarketScreener
Eton Pharmaceuticals licenses Increlex rights abroad - Investing.com
Eton Pharmaceuticals licenses Increlex rights abroad By Investing.com - Investing.com UK
Eton Pharmaceuticals Out-Licenses International Rights to Increlex® - GlobeNewswire
Major Pharma Deal: Eton's Smart Move Unlocks Global Market for Rare Disease Treatment - Stock Titan
Eton Pharmaceuticals Inc (ETON) Shares Down 4.87% on Mar 25 - GuruFocus
CROSSJECT updates on its collaboration with ETON PHARMACEUTICALS, Inc. and the ZENEO® adrenal insufficiency program - The Manila Times
REG-CROSSJECT updates on its collaboration with ETON PHARMACEUTICALS, Inc. and the ZENEO® adrenal insufficiency program - TradingView
CROSSJECT updates on its collaboration with ETON PHARMACEUTICALS, Inc. and the ZENEO® adrenal insufficiency… - Informazione.it
Research Analysts Set Expectations for ETON Q2 Earnings - Defense World
Q3 EPS Estimates for Eton Pharmaceuticals Lifted by B. Riley - Defense World
Eton Pharmaceuticals’ (ETON) “Buy” Rating Reiterated at HC Wainwright - Defense World
Eton Pharmaceuticals Inc (ETON) Stock Price Down 3.79% on Mar 22 - GuruFocus
B. Riley Reiterates Buy Rating for Eton Pharmaceuticals (NASDAQ:ETON) - Defense World
Eton Pharmaceuticals (NASDAQ:ETON) Stock Price Expected to Rise, Craig Hallum Analyst Says - Defense World
Q1 EPS Forecast for Eton Pharmaceuticals Boosted by Analyst - Defense World
5 Analysts Assess Eton Pharmaceuticals: What You Need To Know - Benzinga
Eton Pharmaceuticals, Inc. (NASDAQ:ETON) Q4 2024 Earnings Call Transcript - Insider Monkey
B. Riley Raises Price Target on Eton Pharmaceuticals to $24 From $21, Keeps Buy Rating - MarketScreener
Eton Pharmaceuticals Full Year 2024 Earnings: Revenues Beat Expectations, EPS Lags - Yahoo
Eton Pharmaceuticals Reports Record Q4 Revenue Growth - TipRanks
Eton Pharmaceuticals Reports Strong Growth and Strategic Acquisitions - TipRanks
Eton Pharmaceuticals Inc reports results for the quarter ended December 31Earnings Summary - TradingView
Eton Pharmaceuticals, Inc. (ETON) Reports Q4 Loss, Tops Revenue Estimates - Yahoo Finance
Eton Pharmaceuticals Reports Fourth Quarter 2024 Financial Results - TradingView
Eton Pharmaceuticals Reports Record Q4 2024 Revenue and Successful Product Launches Ahead of Investor Day Conference Call - Nasdaq
Eton Pharmaceuticals Achieves 16th Straight Quarter of Growth, Doubles Product Portfolio - StockTitan
Earnings Scheduled For March 18, 2025 - Benzinga
Eton Pharmaceuticals (NASDAQ:ETON) shareholder returns have been incredible, earning 421% in 5 years - Simply Wall St
(ETON) On The My Stocks Page - news.stocktradersdaily.com
Eton Pharmaceuticals nears NDA submission for new drug By Investing.com - Investing.com Australia
Eton Pharma Plans FDA Filing For ET-600 Oral Desmopressin Next Month, Eyes 2026 Launch - Benzinga India
Eton Pharma rises on study results for rare disease drug - TradingView
12 Health Care Stocks Moving In Friday's Pre-Market Session - Benzinga
Eton's Diabetes Drug Candidate Passes Bioequivalence Study -March 14, 2025 at 07:21 am EDT - Marketscreener.com
Eton Pharmaceuticals nears NDA submission for new drug - Investing.com India
Eton Pharmaceuticals Announces Positive Pivotal Clinical Study Results for Product Candidate ET-600 - Eagle-Tribune
Breakthrough for Pediatric Diabetes: Eton's Liquid Desmopressin Aces Pivotal Trial - StockTitan
Rocket Companies, Novo Nordisk And Other Big Stocks Moving Lower In Monday's Pre-Market Session - Benzinga India
Is 89BIO (ETNB) Stock Outpacing Its Medical Peers This Year? - Yahoo Finance
Eton Pharmaceuticals (ETON) to Release Earnings on Thursday - Defense World
Finanzdaten der Eton Pharmaceuticals Inc-Aktie (ETON)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.71%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):